Zevra Therapeutics, Inc. SEC filings ZVRA
Zevra Therapeutics, Inc. has 870 filings in SEC EDGAR's recent list, going back to May 6, 2008. Its latest annual report, Form 10-K, was filed on Mar 9, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 3, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Nov 3, 2026 (results of operations). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| DEFC14A | Filing | Apr 29, 2025 | — |
| PRRN14A | Filing | Apr 24, 2025 | — |
| DFAN14A | Filing | Apr 23, 2025 | — |
| DEFC14A | Filing | Apr 21, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 17, 2025 | — |
| PRRN14A | Filing | Apr 16, 2025 | — |
| UPLOAD | Letter from the SEC | Apr 11, 2025 | — |
| PREC14A | Filing | Apr 10, 2025 | — |
| PREC14A | Filing | Mar 31, 2025 | — |
| EFFECT | Filing | Jun 13, 2024 | — |
| CORRESP | Letter to the SEC | Jun 10, 2024 | — |
| UPLOAD | Letter from the SEC | Jun 7, 2024 | — |
| EFFECT | Filing | Apr 8, 2024 | — |
| CORRESP | Letter to the SEC | Apr 4, 2024 | — |
| CORRESP | Letter to the SEC | Mar 6, 2024 | — |
| CORRESP | Letter to the SEC | Feb 14, 2024 | — |
| CORRESP | Letter to the SEC | Feb 14, 2024 | — |
| CORRESP | Letter to the SEC | Feb 12, 2024 | — |
| UPLOAD | Letter from the SEC | Feb 7, 2024 | — |
| 425 | Form 425 | Oct 30, 2023 | — |
| EFFECT | Filing | Oct 10, 2023 | — |
| CORRESP | Letter to the SEC | Oct 6, 2023 | — |
| UPLOAD | Letter from the SEC | Oct 4, 2023 | — |
| 425 | Filing | Aug 31, 2023 | — |
| DEFC14A | Filing | Mar 17, 2023 | — |
| PRRN14A | Filing | Mar 16, 2023 | — |
| DEFC14A | Form defc14a | Mar 15, 2023 | — |
| PRER14A | Filing | Mar 13, 2023 | — |
| UPLOAD | Letter from the SEC | Mar 10, 2023 | — |
| PRER14A | Filing | Mar 6, 2023 | — |
| CORRESP | Letter to the SEC | Mar 6, 2023 | — |
| UPLOAD | Letter from the SEC | Mar 3, 2023 | — |
| DFAN14A | Dfan 14a | Mar 3, 2023 | — |
| PREN14A | Filing | Mar 3, 2023 | Mar 3, 2023 |
| PREC14A | Form prec14a | Feb 27, 2023 | — |
| EFFECT | Filing | Feb 1, 2022 | — |
| POS EX | Filing | Jan 28, 2022 | — |
| EFFECT | Filing | Jul 12, 2021 | — |
| CORRESP | Letter to the SEC | Jul 8, 2021 | — |
| EFFECT | Filing | Jul 7, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 7, 2021 | — |
| CORRESP | Letter to the SEC | Jul 2, 2021 | — |
| UPLOAD | Letter from the SEC | Jul 1, 2021 | — |
| D | Filing | Jun 22, 2021 | — |
| EFFECT | Filing | Feb 16, 2021 | — |
| CORRESP | Letter to the SEC | Feb 11, 2021 | — |
| UPLOAD | Letter from the SEC | Feb 11, 2021 | — |
| D | Filing | Feb 4, 2021 | — |
| EFFECT | Filing | Jan 22, 2021 | — |
| CORRESP | Letter to the SEC | Jan 20, 2021 | — |
| UPLOAD | Letter from the SEC | Jan 19, 2021 | — |
| D | Filing | Jan 13, 2021 | — |
| POS EX | Filing | Jan 8, 2021 | — |
| EFFECT | Filing | Jan 7, 2021 | — |
| CERT | Filing | Jan 7, 2021 | — |
| CORRESP | Letter to the SEC | Jan 5, 2021 | — |
| CORRESP | Letter to the SEC | Jan 5, 2021 | — |
| 8-A12B | Filing | Jan 5, 2021 | — |
| UPLOAD | Letter from the SEC | Dec 2, 2020 | — |
| 25-NSE | Delisting notice | Aug 11, 2020 | — |
| EFFECT | Filing | Apr 10, 2020 | — |
| CORRESP | Letter to the SEC | Apr 8, 2020 | — |
| SEC STAFF LETTER | Filing | Feb 28, 2020 | — |
| SEC STAFF LETTER | Filing | Feb 5, 2020 | — |
| D | Filing | Jan 13, 2020 | — |
| D | Filing | Dec 23, 2019 | — |
| CT ORDER | Filing | Nov 20, 2019 | — |
| CORRESP | Letter to the SEC | Oct 31, 2019 | — |
| UPLOAD | Letter from the SEC | Oct 25, 2019 | — |
| CT ORDER | Filing | Mar 22, 2019 | — |
| D | Filing | Nov 2, 2018 | — |
| NT 10-Q | Form nt 10-q | May 16, 2017 | Mar 31, 2017 |
| EFFECT | Filing | Oct 17, 2016 | — |
| CORRESP | Letter to the SEC | Oct 13, 2016 | — |
| UPLOAD | Letter from the SEC | Oct 13, 2016 | — |
| RW | Filing | Feb 3, 2016 | — |
| CT ORDER | Filing | Apr 16, 2015 | — |
| EFFECT | Filing | Apr 15, 2015 | — |
| CORRESP | Letter to the SEC | Apr 13, 2015 | — |
| CERTNAS | Auto-generated paper document | Apr 13, 2015 | — |
| 8-A12B | Form 8-a | Apr 10, 2015 | — |
| CORRESP | Letter to the SEC | Apr 3, 2015 | — |
| UPLOAD | Letter from the SEC | Mar 31, 2015 | — |
| CORRESP | Letter to the SEC | Mar 24, 2015 | — |
| D | Filing | Mar 4, 2015 | — |
| DRSLTR | Filing | Feb 13, 2015 | — |
| DRS/A | Filing | Feb 13, 2015 | — |
| UPLOAD | Letter from the SEC | Feb 10, 2015 | — |
| DRSLTR | Filing | Jan 26, 2015 | — |
| DRS/A | Filing | Jan 26, 2015 | — |
| UPLOAD | Letter from the SEC | Jan 15, 2015 | — |
| DRS | Filing | Dec 19, 2014 | — |
| D | Filing | May 30, 2013 | — |
| D/A | Filing | Jun 30, 2011 | — |
| D | Filing | Jul 15, 2010 | — |
| D/A | Filing | Aug 27, 2009 | — |
| D | Filing | May 1, 2009 | — |
| REGDEX | Auto-generated paper document | May 6, 2008 | — |
Showing 98 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- ZVRA (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Boston, MA
- SEC filer status
- Non-accelerated filer, Smaller reporting company
- SEC CIK
- 1434647
- Former names
- KEMPHARM, INC (until Feb 24, 2023); KEMPHARM INC (until Jun 30, 2011)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.